[CAS NO. 5104-49-4] Flurbiprofen

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [5104-49-4]

Catalog

SLK-S1679

Brand

Selleck

CAS

5104-49-4

DESCRIPTION [5104-49-4]

Overview

MDL	MFCD00079303
Molecular Weight	244.26
Molecular Formula	C15H13FO2
SMILES	FC1=C(C=CC(C(C(O)=O)C)=C1)C2=CC=CC=C2

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	4.0940 mL	20.4700 mL	40.9400 mL
5 mM	0.8188 mL	4.0940 mL	8.1880 mL
10 mM	0.4094 mL	2.0470 mL	4.0940 mL
50 mM	0.0819 mL	0.4094 mL	0.8188 mL

Description

Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs).

In vitro

Flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages in tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Flurbiprofen reduces the number of cells in G1 and G2, and significantly increases their numbers in S phase, suggesting that, Flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment.

In vivo

Flurbiprofen affords significant neuroprotection from ischemic injury as evidenced by reduction in cerebral infarct volume and neurobehavioral deficit. Flurbiprofen significantly reduces an early calcium dependent rise in levels of nitrite and MDA in ischemic brain regions of rats. Flurbiprofen also reduces the proteolytic products (SBDPs) caused by ischemic activation of calcium dependent protease calpain. Flurbiprofen (5 mg/kg and 10mg/kg) significantly attenuates brain ischemia/reperfusion injury in rats, as shown by a reduction in the infarct volume, neurological deficit scores and cell apoptosis. Flurbiprofen not only inhibits the expression of Bax protein and p-GSK-3β, but also increases the expression of Bcl-2 protein, the ratio of Bcl-2/Bax as well as the P-Akt level in rats.

References

[1] King JG Jr, et al. Oncogene,?001, 20(47), 6864-6870.
[2] Mishra V, et al. Neuropharmacology,?010, 59(7-8), 582-588.
[3] Sun B, et al. Biochem Biophys Res Commun,?011, 409(4), 808-813.

Synonyms

[1,1′-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-

4-Biphenylacetic acid, 2-fluoro-α-methyl-

Hydratropic acid, 3-fluoro-4-phenyl-

2-Fluoro-α-methyl[1,1′-biphenyl]-4-acetic acid

3-Fluoro-4-phenylhydratropic acid

2-(2-Fluoro-4-biphenylyl)propionic acid

Flurbiprofen

FP 70

2-(2-Fluoro-4-biphenyl)propionic acid

Froben

FP-A

Ansaid

Flugalin

U 27182

2-(2-Fluoro-4-biphenylyl)propanoic acid

2-Fluoro-α-methyl-4-diphenylacetic acid

2-Fluoro-α-methyl-4-biphenylacetic acid

dl-2-(2-Fluoro-4-biphenylyl)propionic acid

(±)-Flurbiprofen

Racemic flurbiprofen

dl-Flurbiprofen

rac-Flurbiprofen

Stayban

Adfeed

Antadys

Cebutid

Zepolas

Flurofen

BTS 18322

2-(2-Fluoro-1,1′-biphenyl-4-yl)propanoic acid

Fluribiprofen

Fluroben

Synalgo

Flurbifen

2-(3-Fluoro-4-phenylphenyl)propanoic acid